Spectroscopic Investigations, Quantum Chemical, Molecular Docking and Drug Likeness Studies of 3-Fluorobenzamide

COMPUTATIONAL STUDIES OF 3-FLUOROBENZAMIDE AS ANTI-CANCER AGENT

Abstract

A significant class of pharmaceuticals due to their biological properties and anti-tumor properties are benzamide derivatives. Density Functional Theory (DFT) calculations involving basis sets, 6-31++G(d,p) and 6-311++G(d,p), have been employed to understand the molecular characteristics of 3-fluorobenzamide. The FTIR and FT-Raman spectroscopies have been used to characterize the vibrational spectra of the molecule. The estimated structural parameters and vibrational frequencies have been analyzed and compared with the experimental findings. The frontier orbital energy gap of the molecule is determined to be 5.521 eV. According to UV-Vis study, the π→π* transition occurs because the ring's C-C bonds function as a leading electron acceptor, while the oxygen (O13) and nitrogen (N14) atoms can act as electron donors. The density of states (DOS) spectrum has 84 electrons, 42α and 42β electrons combined. The Natural Bond Orbital (NBO) results showed that the lone pair transition of F8 and N14 atoms to π*(C3-C4) and π*(C12-O13) indicated a significant stabilizing energy of 17.84 and 43.56 Kcal∙mol⁻¹. The region around the oxygen atom (electrophilic) and amino group hydrogen atoms (nucleophilic) have been analyzed. For ¹H and ¹³C NMR, the predicted chemical shifts were 1.55 to 8.95 ppm and 127.04 to 193.09 ppm, respectively. The binding energies of human matrix metalloproteinase-2, an inhibitor of ovarian cancer, were found to be −6.5 Kcal∙mol⁻¹, those of human progesterone and allosteric inhibitor, inhibitors of breast cancer, to be −6.6 and −5.4 Kcal∙mol⁻¹, and those of histone deacetylases, an inhibitor of leukemia cancer, to be −6.5 Kcal∙mol⁻¹, These are comparable to the binding energies of standard drugs (cytarabine, anastrozole, and carboplatin). ADMET predictions have been employed and the chemical can effectively cure cancers of the ovaries, breast and leukemia while reducing the adverse effects of medical procedures.